TipRanks’ Trending Stocks tool allows users to filter activity over the past 30 days, seven days, or even the last 72 hours to see which stocks are drawing the most attention. Checking this page regularly can help you stay ahead of the latest market movers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Here are the top three most‑rated stocks over the past 72 hours (listed in descending order). Click any ticker to explore all of TipRanks’ unique datasets for that stock.
Neurocrine Biosciences (NBIX) – Neurocrine Biosciences develops drugs for brain, hormone, and mental health disorders. The stock has received 11 ratings over the past 72 hours after the company announced $2.9 billion acquisition of biotech firm Soleno Therapeutics (SLNO). Soleno has created the first approved drug for extreme hunger in Prader-Willi syndrome patients.
It earned an analyst consensus of Strong Buy and carries an average price target of $183.90, indicating a 37.2% upside potential.
Viridian Therapeutics (VRDN) – This biopharmaceutical firm develops innovative drugs for serious rare diseases, especially autoimmune conditions like thyroid eye disease. VRDN stock has been rated by ten analysts in the past three days. The ratings came after rival Amgen’s (AMGN) Phase 3 trial succeeded with a subcutaneous version of Tepezza for moderate-to-severe active thyroid eye disease, a condition Viridian also targets with its own treatments.
The analyst consensus on the stock is a Strong Buy. With an average price target of $33.83, the stock has an implied upside potential of 143.4%.
PayPay Corporation (PAYP) – PayPay Corp. is a Japanese fintech company that runs a mobile app combining payments, banking, credit, investments, and daily services into one smartphone hub to push a cashless society. The stock is also trending, having been rated nine times in the past 72 hours. The ratings come as PayPay completed about 3-4 weeks post its March 12 listing, with trading stabilized and full financials reviewed.
The analyst consensus on the stock is a Moderate Buy, with an average price target of $25.49, suggesting an upside of 35.3%.